Literature DB >> 21553073

[Managing comorbidities of inflammatory rheumatic diseases].

K de Groot1, E Märker-Hermann.   

Abstract

Patients with inflammatory rheumatic diseases often suffer from considerable comorbidities that can arise due to the chronic systemic inflammatory activity of the rheumatic disease itself, disorders of immune defense, or as a result of antirheumatic treatment; they can also occur independently. For example, almost 50% of patients with rheumatoid arthritis already exhibit two further chronic diseases at the time of initial manifestation. With regard to the elevated mortality observed in patients with rheumatism, particularly cardiovascular morbidity and increased predisposition to infections are of note. In addition, this article addresses further important possible concomitant diseases, i.e., osteoporosis and tumor diseases. A ground rule is to identify comorbidities and treat them just as diligently as the underlying rheumatic disease so that the patient with rheumatism should be accompanied by an interdisciplinary team of internists during each phase of the disease. Effective control of the systemic inflammatory activity may serve to reduce the risk of certain cardiovascular and neoplastic comorbidities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21553073     DOI: 10.1007/s00108-010-2769-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  61 in total

Review 1.  Pneumocystis pneumonia.

Authors:  Charles F Thomas; Andrew H Limper
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

Review 2.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

3.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

4.  [Comorbidity in rheumatoid arthritis of early onset. Effects on outcome parameters].

Authors:  G Westhoff; C Weber; A Zink
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

5.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.

Authors:  L Guillevin; J F Cordier; F Lhote; P Cohen; B Jarrousse; I Royer; P Lesavre; C Jacquot; P Bindi; P Bielefeld; J F Desson; F Détrée; A Dubois; E Hachulla; B Hoen; D Jacomy; C Seigneuric; D Lauque; M Stern; M Longy-Boursier
Journal:  Arthritis Rheum       Date:  1997-12

6.  Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.

Authors:  Michael S Lee; Scott D Smith; Anat Galor; Gary S Hoffman
Journal:  Arthritis Rheum       Date:  2006-10

Review 7.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

8.  Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

9.  Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis.

Authors:  Mikkel Faurschou; Lene Mellemkjaer; Inge Juul Sorensen; Bjarne Svalgaard Thomsen; Lene Dreyer; Bo Baslund
Journal:  Arthritis Rheum       Date:  2009-04

Review 10.  Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis.

Authors:  J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2009-03-20       Impact factor: 4.330

View more
  2 in total

Review 1.  [Promotion of physical activity for older patients with rheumatism : Characteristics of inflammatory rheumatic diseases against the background of physical activity recommendations].

Authors:  A Golla; K Mattukat; W Mau
Journal:  Z Rheumatol       Date:  2019-03       Impact factor: 1.372

2.  [Multimorbidity in elderly rheumatic patients part 1].

Authors:  H-J Lakomek; T Brabant; M Lakomek; D Lüttje
Journal:  Z Rheumatol       Date:  2013-08       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.